Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Other Operating Expenses (2017 - 2025)

Tandem Diabetes Care filings provide 8 years of Other Operating Expenses readings, the most recent being $75.2 million for Q1 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to $75.2 million in Q1 2025 year-over-year; TTM through Dec 2025 was $75.2 million, a 7521800.0% increase, with the full-year FY2025 number at $75.2 million, changed N/A from a year prior.
  • Other Operating Expenses hit $75.2 million in Q1 2025 for Tandem Diabetes Care, up from -$1000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $78.8 million in Q1 2023 to a low of -$1000.0 in Q4 2024.
  • Median Other Operating Expenses over the past 4 years was $31.0 million (2022), compared with a mean of $37.0 million.